Science Explorer Back to mapMap
Discussion
Institution · Synimmune (Germany)

Most cited papers from Synimmune (Germany)

Synimmune (Germany)

What are the most cited papers from Synimmune (Germany)?

The most cited paper from Synimmune (Germany) is "Genetically engineered CAR NK cells display selective cytotoxicity against FLT3‐positive B‐ALL and inhibit in vivo leukemia growth" (Sarah Oelsner, Anja Waldmann, Arne Billmeier et al., 2019), with 87 citations. Next come "Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia" (57) and "γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay" (48).

Showing 15 of 15 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Genetically engineered CAR NK cells display selective cytotoxicity against FLT3‐positive B‐ALL and inhibit in vivo leukemia growth Sarah Oelsner, Anja Waldmann, Arne Billmeier et al. · International Journal of Cancer 12 Mar 2019 87
2 Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia Michael Durben, Dominik Schmiedel, Martin Hofmann et al. · Molecular Therapy Open access 12 Jan 2015 57
3 γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay Ursula Jördis Eva Seidel, Fabian Vogt, Ludger Große‐Hovest et al. · Frontiers in Immunology Open access 2 Dec 2014 48
4 Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody Ursula Jördis Eva Seidel, Patrick Schlegel, Ludger Große‐Hovest et al. · Molecular Therapy Open access 6 Jul 2016 21
5 Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease Jonas S. Heitmann, Richard F. Schlenk, Daniela Dörfel et al. · Journal of Hematology & Oncology Open access 17 Aug 2023 17
6 A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells Kristina Nalivaiko, Martin Hofmann‐Apitius, Karina Kober et al. · Molecular Therapy Open access 19 Nov 2015 9
7 Hydrophobic Interaction Chromatography for Bottom-Up Proteomics Analysis of Single Proteins and Protein Complexes Michal Rackiewicz, Ludger Große‐Hovest, Andrew J. Alpert et al. · Journal of Proteome Research 9 May 2017 6
8 IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial Lukas Bunse et al. · Nature Cancer Open access Jul 2026 4
9 First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease Jonas S. Heitmann, Daniela Dörfel, Sabine C. Käyser et al. · Blood 4 Nov 2020 4
10 Induction of NK Cell Reactivity Against Myeloid Leukemia By a Novel Fc-Optimized CD133 Antibody Kathrin Rothfelder, Samuel Koerner, Maya Caroline Andre et al. · Blood 3 Dec 2015 3
11 Development and Preclinical Characterization of an Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity Against Myeloid Leukemia Samuel Koerner, Julia Leibold, Ludger Große‐Hovest et al. · Blood 6 Dec 2014 2
12 Induction of NK and T Cell Immune Responses Against Leukemia Cells By Bispecific NKG2D-CD16 and -CD3 Fusion Proteins Samuel Koerner, Lothar Kanz, Ludger Große‐Hovest et al. · Blood 3 Dec 2015 1
13 Programmable Edge-to-Edge Assembly of RNA Nanostructures Cody W. Geary, Mai P. Tran, Erik Poppleton et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 31 Mar 2026 0
14 An Fc-Engineered CD133 Antibody for Induction of NK Cell Reactivity Against Cancer Cells Kathrin Rothfelder, Julia Leibold, Ludger Große‐Hovest et al. · Blood 6 Dec 2014 0
15 Bispecific Antibodies for the Treatment of Cancer: The Challenges of Translation Gundram Jung, Ludger Große‐Hovest Book chapter 2014 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.